Evidence Before Claims.

This clinical report looked at 116 patients in real-world practice who used a high-purity curcumin supplement (Flexofytol) for fibromyalgia or gout – conditions marked by chronic pain.The majority of patients experienced a notable reduction in pain symptoms, with some fibromyalgia sufferers reporting improvement within 24–48 hours of starting curcumin.

The curcumin was well tolerated (only minor issues like occasional diarrhea), and although it did not markedly change sleep disturbances in fibromyalgia, it provided clear analgesic benefits.The authors suggest such a curcumin-based approach is a useful, safe alternative or complement to conventional pain treatments for fibromyalgia and gout.

This randomized placebo-controlled trial demonstrated that a Boswellia serrata extract (a key ingredient related to ProleevaMax’s formula) produced rapid and significant relief in osteoarthritis patients.

Over 98 patients completed 90 days of supplementation, resulting in up to a 61% reduction in knee pain scores and ~70% improvements in joint stiffness and function, with some benefits evident within just 5 days.Inflammatory biomarkers (TNF-α, CRP, IL-6) dropped in the treated groups, and no serious adverse events occurred, confirming Boswellia’s safety and its effectiveness in supporting joint health.

Chronic Inflammatory conditions are long-term inflammatory changes that occur in the body of an individual. These diseases and conditions predispose the individual to a variety of harmful stimuli that affect the health of a person.Apart from practicing dietary changes and lifestyle modifications, many dietary supplements also help take care of the body of such individuals.PROLEEVAMAX™ is one such supplement that helps people meet their daily requirements of multivitamins and other nutrients.

It helps restore the balance of neurotransmitters in the brain and makes the body strong enough to fight off pain and metabolic disorders. It is a safe and effective supplement and is recommended to be taken daily for optimal results.

A comprehensive review of Varvimax (the nutraceutical blend in ProleevaMax) concluded it is a safe and promising treatment for chronic pain associated with arthritis and fibromyalgia.

The paper highlights that Varvimax’s all-natural composition (rich in anthocyanins like astaxanthin, plus amino acids and flavonoids) exhibits significant anti-inflammatory and antioxidant properties, helping reduce pain and inflammation while improving joint function in patients.

Only mild gastrointestinal side effects were noted, and the authors call for further research to solidify long-term efficacy.

In this pre-clinical study, scientists investigated astaxanthin – a powerful natural antioxidant also present in Varvimax – using a rodent model of spinal nerve injury. Astaxanthin-treated mice showed significant reductions in neuropathic pain behaviors, correlating with a suppression of key inflammatory signaling in the spinal cord.Specifically, astaxanthin inhibited the activation of ERK1/2, p38 MAPK, and NF-κB, and lowered inflammatory cytokines (IL-1β, IL-6, IL-17, TNF-α) at the injury site.

These molecular changes translated into tangible pain relief, suggesting astaxanthin is a promising candidate for reducing nerve pain hypersensitivity and underscoring the therapeutic potential of the compound’s antioxidant/anti-inflammatory action in chronic pain management.

This groundbreaking mechanistic study revealed how the omega-3 fatty acid EPA (an ingredient in ProleevaMax’s formula) exerts potent pain-relieving effects.Researchers found EPA blocks the vesicular nucleotide transporter (VNUT), which in turn attenuates both neuropathic and inflammatory pain in mouse model.In mice with nerve injury or inflammation, EPA administration produced analgesic effects stronger than some existing pain medications, with minimal side effects.

Notably, mice lacking the VNUT protein did not gain pain relief from EPA, confirming the target. These findings suggest EPA could be leveraged as a unique nutrient-based strategy to combat chronic pain via modulation of purinergic signaling.